Veeva Systems Partners with Boehringer Ingelheim to Launch 'One Medicine Platform'

The One Medicine Platform, powered by Veeva Development Cloud, represents the culmination of the collaboration first initiated in March 2022. By unifying critical functions, Boehringer Ingelheim aims to optimize trial efficiency, improve collaboration with research sites, and ultimately accelerate the delivery of groundbreaking medicines to patients suffering from previously incurable diseases.

Oliver Fink, head of learning, process, and digitalization at Boehringer Ingelheim, expressed enthusiasm about the partnership, stating, "Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world." Fink emphasized the flexibility and efficiency provided by Veeva Development Cloud as a critical component in designing and executing clinical studies.

Rik van Mol, senior vice president of Veeva Development Cloud, highlighted the platform's role in breaking down silos across various teams involved in drug development. "By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and accelerates drug development and approvals," he remarked. This initiative is seen as a pivotal milestone in Veeva and Boehringer's joint mission to modernize clinical trials through the innovative use of data and technology, ultimately aiming for improved patient outcomes.

Veeva Development Cloud serves as the technological backbone for the One Medicine Platform, integrating clinical, quality, regulatory, and safety applications into a cohesive tool. This end-to-end solution simplifies business processes, enhancing operational excellence throughout the drug development lifecycle.

The collaboration is not only a strategic alignment between two industry leaders but also a testament to the growing reliance on technology in the life sciences sector. By leveraging the capabilities of Veeva Development Cloud, Boehringer Ingelheim can navigate the increasingly complex landscape of drug development with greater agility and compliance.

Boehringer Ingelheim is a prominent biopharmaceutical company dedicated to both human and animal health. Established in 1885, the company prides itself on being one of the industry's leading investors in research and development, focusing on creating innovative therapies to address significant unmet medical needs. With a global workforce of over 53,500 employees, Boehringer operates in more than 130 markets, committed to fostering a healthier and more sustainable future.

Veeva Systems, recognized as the global leader in cloud software tailored for the life sciences industry, is dedicated to innovation, product excellence, and customer success. Serving over 1,000 clients, from leading biopharmaceutical companies to emerging biotech firms, Veeva operates as a Public Benefit Corporation, balancing the interests of all stakeholders, including customers, employees, and shareholders.

The launch of the One Medicine Platform signifies a monumental leap forward in the collaboration between Veeva Systems and Boehringer Ingelheim. By harnessing the power of Veeva Development Cloud, the partnership aims to redefine the clinical trial landscape, fostering enhanced efficiency and ultimately improving patient outcomes in the quest for new medical breakthroughs. As the biopharmaceutical industry continues to evolve, this initiative reflects the critical importance of data integration and technological advancement in delivering effective healthcare solutions.